Role of DAT-SPECT in the diagnostic work up of parkinsonism.
about
The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disordersThe role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 2The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohortLongitudinal follow-up of SWEDD subjects in the PRECEPT StudyThe diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review.The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1.123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders.Physiology of psychogenic movement disordersCSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.Dopamine transporter imaging using 99mTc-TRODAT-1 SPECT in Parkinson's diseaseDistinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study.iPLA2β knockout mouse, a genetic model for progressive human motor disorders, develops age-related neuropathology.Pharmacotherapy in the management of early Parkinson's disease: cost-effectiveness and patient acceptability.Critical aspects of clinical trial design for novel cell and gene therapies.Fully Automated Quantification of the Striatal Uptake Ratio of [(99m)Tc]-TRODAT with SPECT Imaging: Evaluation of the Diagnostic Performance in Parkinson's Disease and the Temporal Regression of Striatal Tracer Uptake.Levodopa Responsiveness in Adult-onset Lower Limb Dystonia is Associated with the Development of Parkinson's DiseaseParkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion.The predictive value of SS-16 in clinically diagnosed Parkinson's disease patients: comparison with (99m)Tc-TRODAT-1 SPECT scans.Single photon-emission computed tomography imaging in early Parkinson's disease.Imaging dopamine transporters in Parkinson's disease.A review of current and novel levodopa formulations for the treatment of Parkinson's disease.Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease.Biomarkers in Parkinson's disease: a funder's perspective.The Mechanisms of Traditional Chinese Medicine Underlying the Prevention and Treatment of Parkinson's Disease.The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies.Study of the prevalence of Parkinson's disease using dopamine transporter imaging.An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.Central and peripheral dopamine transporter reduction in Parkinson's disease.The neurobiology of impulse control disorders in Parkinson's disease: from neurotransmitters to neural networks.Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes.Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6.Weighted registration of 123I-FP-CIT SPECT images improves accuracy of binding potential estimates in pathologically low striatal uptake.The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes.Inter- and intra-observer reproducibility of quantitative analysis for FP-CIT SPECT in patients with DLB.Robust, fully automatic delineation of the head contour by stereotactical normalization for attenuation correction according to Chang in dopamine transporter scintigraphy.Parkinson disease: Can dopamine transporter imaging define early PD?Interobserver variability, and visual and quantitative parameters of (123)I-FP-CIT SPECT (DaTSCAN) studies.Baseline [(123) I]FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease.Positron emission tomography in Parkinson's disease: insights into impulsivity.The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases.
P2860
Q22241325-849F625B-87FD-4287-B9ED-6132441C86E8Q27011665-59B5D178-CE8F-47BD-B683-AE78277A9193Q28076121-446847A5-B160-4CD2-B290-515256E06817Q30578973-9700E89F-F1E1-4B49-A9B3-7A95E00FDA0FQ30635471-16C43B63-385E-4796-AA0B-8EC5FF10EEECQ30829363-60F99091-37D7-4615-BAA3-CCBE484069D3Q33760571-B4339F9C-6370-472A-9E9F-FFD78328EEE6Q33987225-4E671EBA-4EF2-4A7B-8218-B8303448428CQ33994583-1937A8B9-8CF1-4BEE-AA77-6354C9E33C32Q34066195-EAD3B929-6273-4B50-806A-8E16B7514EF1Q34376763-0AD6F316-B80D-4410-85E4-DBBF3799B3ADQ35189288-C241F4F0-A861-429C-B197-D504E66EDB92Q35205344-56EBFD8C-6788-4751-A32D-EFBE0AC9ECADQ35664438-4A9D4756-688B-4CD2-8BD4-593624DEDD92Q36022062-53253520-2DDF-47A2-A975-D41F2EF1B11EQ36776883-F4CAB6A0-FE2A-4120-9D22-64D564F2EAB4Q37086136-8176CE8F-4350-487F-814D-DD692010B4D5Q37192609-A4BEB476-B933-443A-818B-987E7B084661Q37352055-795DD774-6247-4CB6-9CB5-ADE4CA5DC8B0Q37800096-E71FBFBD-8F28-42F8-8C7C-ECCFD23CE501Q38740274-1A0F2889-50E5-4BB8-B9B6-D1357C5B46EEQ39119095-699AF2E7-D859-4AF3-93CA-5604179D2E74Q39827858-5D7C6645-EEDE-4BC1-B0AF-940BB23BB6E0Q42362529-61C96FDD-91A1-4FCC-8A40-1528A27C9D37Q43164212-DD24E42A-D77B-4059-8448-805CDB92A08DQ43215229-96D74EA1-6E22-424C-8D42-F2336F9C6932Q46152351-BA89F627-66F0-4754-889C-BF104B6CE7B9Q46211031-5C438E59-2AB5-455C-8100-6A6CB99A266EQ47830362-815A4114-87CC-48C3-BBF8-7105BFB6FF43Q47911714-A7D483CF-D9B5-45E0-82D4-37EC10B2D590Q48019527-A5F1D4BD-5B1D-4771-8480-D170E59E26D4Q48095805-803543E0-1645-4EB1-8930-00E8022858DFQ48103234-E0A32438-1FC4-46B4-9CD8-4AF006C5B440Q48111729-7763D93D-A6F4-4C93-8BD8-6E63FE16E9B8Q48309245-C513FB7E-5776-4EFC-8D35-C36B76634622Q48671361-2F782E0C-4DF9-4BA6-AC11-269AC5B60898Q48716972-5EB5E07A-AFFA-4C36-8B08-1255135FCF49Q49136792-341EA637-5246-49F6-BBC3-CC4551A72B63Q50069106-312F0EC5-AEB6-418E-9709-312939D9055AQ50264497-03BB9BDA-A37E-4468-848D-58EBA992BA70
P2860
Role of DAT-SPECT in the diagnostic work up of parkinsonism.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Role of DAT-SPECT in the diagnostic work up of parkinsonism.
@ast
Role of DAT-SPECT in the diagnostic work up of parkinsonism.
@en
type
label
Role of DAT-SPECT in the diagnostic work up of parkinsonism.
@ast
Role of DAT-SPECT in the diagnostic work up of parkinsonism.
@en
prefLabel
Role of DAT-SPECT in the diagnostic work up of parkinsonism.
@ast
Role of DAT-SPECT in the diagnostic work up of parkinsonism.
@en
P2093
P2860
P50
P356
P1433
P1476
Role of DAT-SPECT in the diagnostic work up of parkinsonism.
@en
P2093
Christoph Scherfler
Donald Grosset
Johannes Schwarz
Kenneth Marek
P2860
P304
P356
10.1002/MDS.21505
P407
P577
2007-07-01T00:00:00Z